Which drug or drug delivery system can change clinical practice for brain tumor therapy?

Neuro-Oncology

Volumn 15, Issue 6, 2013, Pages 656-669

  Siegal, Tali ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

blood brain barrier; brain drug delivery; brain tumor; brain tumor therapy; clinical practice; CNS; drug development; drug efflux mechanism

Indexed keywords

ACETYLCYSTEINE; ALKYLATING AGENT; AMIFOSTINE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; AVIDIN; BIOTIN; BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; CYCLOSPORIN A; DOXORUBICIN; DRUG CARRIER; ELACRIDAR; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; LENTIVIRUS VECTOR; MANNITOL; METHOTREXATE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; NANOCARRIER; PEPTIDE; POLYMER; TEMOZOLOMIDE; TRASTUZUMAB; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; ZOSUQUIDAR;

ANTIANGIOGENIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TUMOR; BURKITT LYMPHOMA; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER THERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CHEMICAL MODIFICATION; CLINICAL PRACTICE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TRANSPORT; EXOSOME; GLIOBLASTOMA; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; LIPOPHILICITY; LYMPHOBLASTOMA; LYMPHOMA; MAGNETIC FIELD; MEDICAL LITERATURE; MEMBRANE TRANSPORT; NEUROTOXICITY; NONHUMAN; OSMOSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); TUMOR LOCALIZATION; TUMOR VOLUME;

BLOOD-BRAIN BARRIER; BRAIN DRUG DELIVERY; BRAIN TUMOR; BRAIN TUMOR THERAPY; CLINICAL PRACTICE; CNS; DRUG DEVELOPMENT; DRUG EFFLUX MECHANISM;

ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; DRUG DELIVERY SYSTEMS; HUMANS; PHYSICIAN'S PRACTICE PATTERNS;

EID: 84878338687     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not016     Document Type: Article

References (151)

1. Muldoon LL, Soussain C, Jahnke K, et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol. 2007; 25: 2295-2305.
2. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002; 359: 1011-1018.
3. Stupp R, Hegi ME, Gilbert MR, Chakravarti A. Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol. 2007; 25: 4127-4136.
4. Polivka J, Jr., Polivka J, Rohan V, Topolcan O, Ferda J. New molecularly targeted therapies for glioblastoma multiforme. Anticancer Research. 2012; 32: 2935-2946.
5. Schneider G, Kirchin MA, Pirovano G, et al. Gadobenate dimeglumine-enhanced magnetic resonance imaging of intracranial metastases: effect of dose on lesion detection and delineation. J Magn Reson Imaging. 2001; 14: 525-539.
6. Groothuis D, Vick NA. Brain tumors and the blood-brain barrier. Trends in Neuroscience. 1982; 5: 232.
7. Vick NA, Khandekar JD, Bigner DD. Chemotherapy of brain tumors. Arch Neurol. 1977; 34: 523-526.
8. Jain RK. Barriers to drug delivery in solid tumors. Sci Am. 1994; 271: 58-65.
9. Netti PA, Baxter LT, Boucher Y, Skalak R, Jain RK. Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery. Cancer Res. 1995; 55: 5451-5458.
10. Jain RK. Normalization of tumor vasculature: an emerging concept in anti-angiogenic therapy. Science. 2005; 307: 58-62.
11. Agarwal S, Elmquist WF. Insight into the cooperation of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the bloodbrain barrier: a case study examining sorafenib efflux clearance. Molecular pharmaceutics. 2012; 9: 678-684.
12. On NH, Mitchell R, Savant SD, Bachmeier CJ, Hatch GM, Miller DW. Examination of blood-brain barrier (BBB) integrity in a mouse brain tumor model. J Neurooncol. 2013; 11: 133-143.
13. Naumov GN, Bender E, Zurakowski D, et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst. 2006; 98: 316-325.
14. di Tomaso E, Snuderl M, Kamoun WS, et al. Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Res. 2011; 71: 19-28.
15. Keunen O, Johansson M, Oudin A, et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA. 2011; 108: 3749-3754.
16. Blakeley J, Portnow J. Microdialysis for assessing intratumoral drug disposition in brain cancers: a tool for rational drug development. Expert Opin Drug Metab Toxicol. 2010; 6: 1477-1491.
17. Bidros DS, Vogelbaum MA. Novel drug delivery strategies in neurooncology. Neurotherapeutics. 2009; 6: 539-546.
18. Laquintana V, Trapani A, Denora N, Wang F, Gallo JM, Trapani G. New strategies to deliver anticancer drugs to brain tumors. Expert Opin Drug Deliv. 2009; 6: 1017-1032.
19. Soni V, Jain A, Khare P, Gulbake A, Jain SK. Potential approaches for drug delivery to the brain: past, present, and future. Crit Rev Ther Drug Carrier Syst. 2010; 27: 187-236.
20. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987-996.
21. Patel MM, Goyal BR, Bhadada SV, Bhatt JS, Amin AF. Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs. 2009; 23: 35-58.
22. Haga S, Hinoshita E, Ikezaki K, et al. Involvement of the multidrug resistance protein 3 in drug sensitivity and its expression in human glioma. Jpn J Cancer Res. 2001; 92: 211-219.
23. Rittierodt M, Harada K. Repetitive doxorubicin treatment of glioblastoma enhances the PGP expression-a special role for endothelial cells. Exp Toxicol Pathol. 2003; 55: 39-44.
24. Becker I, Becker KF, Meyermann R, Hollt V. The multidrug-resistance gene MDR1 is expressed in human glial tumors. Acta Neuropathol. 1991; 82: 516-519.
25. Agarwal S, Manchanda P, Vogelbaum MA, Ohlfest JR, Elmquist WF. Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in a orthotopic rat xenograft model of glioma. Drug Metabolism and Disposition: The Biological Fate of Chemicals. 2013; 41: 33-39.
26. Rautio J, Laine K, Gynther M, Savolainen J. Prodrug approaches for CNS delivery. The AAPS Journal. 2008; 10: 92-102.
27. Genka S, Deutsch J, Shetty UH, et al. Development of lipophilic anticancer agents for the treatment of brain tumors by the esterification of water-soluble chlorambucil. Clinical and Experimental Metastasis. 1993; 11: 131-140.
28. Pardridge WM. Blood-brain barrier delivery. Drug Discovery Today. 2007; 12: 54-61.
29. Pardridge WM. Drug transport across the blood-brain barrier. Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 2012; 32: 1959-1972.
30. Pavan B, Dalpiaz A. Prodrugs and endogenous transporters: are they suitable tools for drug targeting into the central nervous system? Current Pharmaceutical Design. 2011; 17: 3560-3576.
31. Guo L, Ren J, Jiang X. Perspectives on brain-targeting drug delivery systems. Current Pharmaceutical Biotechnology. 2012; 13: 2310-2318.
32. Pardridge WM, Boado RJ. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. Methods in Enzymology. 2012; 503: 269-292.
33. Kurbacher CM, Mallmann PK. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721). Anticancer Research. 1998; 18: 2203-2210.
34. Dickey DT, Muldoon LL, Doolittle ND, Peterson DR, Kraemer DF, Neuwelt EA. Effect of N-acetylcysteine route of administration on chemoprotection against cisplatin-induced toxicity in rat models. Cancer Chemotherapy and Pharmacology. 2008; 62: 235-241.
35. Larochelle A, Choi U, Shou Y, et al. In vivo selection of hematopoietic progenitor cells and temozolomide dose intensification in rhesus macaques through lentiviral transduction with a drug resistance gene. The Journal of Clinical Investigation. 2009; 119: 1952-1963.
36. Takahashi S, Aiba K, Ito Y, et al. Pilot study of MDR1 gene transfer into hematopoietic stem cells and chemoprotection in metastatic breast cancer patients. Cancer Science. 2007; 98: 1609-1616.
37. Hoelzer D, Ludwig WD, Thiel E, et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood. 1996; 87: 495-508.
38. Siegal T, Goldschmidt N. CNS prophylaxis in diffuse large B-cell lymphoma: if, when, how and for whom? Blood Reviews. 2012; 26: 97-106.
39. DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ, Radiation Therapy Oncology Group S. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol. 2002; 20: 4643-4648.
40. Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus highdose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009; 374: 1512-1520.
41. Dukic S, Heurtaux T, Kaltenbach ML, et al. Pharmacokinetics of methotrexate in the extracellular fluid of brain C6-glioma after intravenous infusion in rats. Pharm Res. 1999; 16: 1219-1225.
42. Dukic SF, Heurtaux T, Kaltenbach ML, Hoizey G, Lallemand A, Vistelle R. Influence of schedule of administration on methotrexate penetration in brain tumours. Eur J Cancer. 2000; 36: 1578-1584.
43. Hiraga S, Arita N, Ohnishi T, et al. Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas. J Neurosurg. 1999; 91: 221-230.
44. Blakeley JO, Olson J, Grossman SA, He X, Weingart J, Supko JG. Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study. J Neurooncol. 2009; 91: 51-58.
45. Gelman M, Chakeres DW, Newton HB. Brain tumors: complications of cerebral angiography accompanied by intraarterial chemotherapy. Radiology. 1999; 213: 135-140.
46. Osztie E, Varallyay P, Doolittle ND, et al. Combined intraarterial carboplatin, intraarterial etoposide phosphate, and IV Cytoxan chemotherapy for progressive optic-hypothalamic gliomas in young children. AJNR Am J Neuroradiol. 2001; 22: 818-823.
47. Tfayli A, Hentschel P, Madajewicz S, et al. Toxicities related to intraarterial infusion of cisplatin and etoposide in patients with brain tumors. J Neurooncol. 1999; 42: 73-77.
48. Angelov L, Doolittle ND, Kraemer DF, et al. Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience. J Clin Oncol. 2009; 27: 3503-3509.
49. Nakagawa H, Fujita T, Izumoto S, et al. cis-diamminedichloroplatinum (CDDP) therapy for brain metastasis of lung cancer. I. Distribution within the central nervous system after intravenous and intracarotid infusion. J Neurooncol. 1993; 16: 61-67.
50. Kroll RA, Pagel MA, Muldoon LL, Roman-Goldstein S, Fiamengo SA, Neuwelt EA. Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: a comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers. Neurosurgery. 1998; 43: 879-886. discussion 886-879.
51. Borlongan CV, Emerich DF. Facilitation of drug entry into the CNS via transient permeation of blood brain barrier: laboratory and preliminary clinical evidence from bradykinin receptor agonist, Cereport. Brain Res Bull. 2003; 60: 297-306.
52. Black KL, Ningaraj NS. Modulation of brain tumor capillaries for enhanced drug delivery selectively to brain tumor. Cancer Control: Journal of the Moffitt Cancer Center. 2004; 11: 165-173.
53. Cote J, Savard M, Bovenzi V, et al. Selective tumor blood-brain barrier opening with the kinin B2 receptor agonist [Phe(8)psi(CH(2)NH) Arg(9)]-BK in a F98 glioma rat model: an MRI study. Neuropeptides. 2010; 44: 177-185.
54. Chen PY, Liu HL, Hua MY, et al. Novel magnetic/ultrasound focusing system enhances nanoparticle drug delivery for glioma treatment. Neuro Oncol. 2010; 12: 1050-1060.
55. Liu HL, Hua MY, Chen PY, et al. Blood-brain barrier disruption with focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment. Radiology. 2010; 255: 415-425.
56. Deng CX. Targeted drug delivery across the blood-brain barrier using ultrasound technique. Therapeutic Delivery. 2010; 1: 819-848.
57. Siegal T, Rubinstein R, Bokstein F, et al. In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans. J Neurosurg. 2000; 92: 599-605.
58. Zylber-Katz E, Gomori JM, Schwartz A, Lossos A, Bokstein F, Siegal T. Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma. Clin Pharmacol Ther. 2000; 67: 631-641.
59. Marchi N, Angelov L, Masaryk T, et al. Seizure-promoting effect of blood-brain barrier disruption. Epilepsia. 2007; 48: 732-742.
60. Joshi S, Ergin A, Wang M, et al. Inconsistent blood brain barrier disruption by intraarterial mannitol in rabbits: implications for chemotherapy. J Neurooncol. 2011; 104: 11-19.
61. Ergin A, Wang M, Zhang JY, et al. The feasibility of real-time in vivo optical detection of blood-brain barrier disruption with indocyanine green. J Neurooncol. 2012; 106: 551-560.
62. Cloughesy TF, Black KL. Pharmacological blood-brain barrier modification for selective drug delivery. J Neurooncol. 1995; 26: 125-132.
63. Barichello T, Fagundes GD, Generoso JS, et al. Brain-blood barrier breakdownand pro-inflammatorymediators in neonate rats submitted meningitis by Streptococcus pneumoniae. Brain Research. 2012; 1471: 162-168.
64. Kebir H, Kreymborg K, Ifergan I, et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nature Medicine. 2007; 13: 1173-1175.
65. Bartus RT, Elliott PJ, Dean RL, et al. Controlled modulation of BBB permeability using the bradykinin agonist, RMP-7. Exp Neurol. 1996; 142: 14-28.
66. Ford J, Osborn C, Barton T, Bleehen NM. A phase I study of intravenous RMP-7 with carboplatin in patients with progression of malignant glioma. Eur J Cancer. 1998; 34: 1807-1811.
67. Tempany CM, McDannold NJ, Hynynen K, Jolesz FA. Focused ultrasound surgery in oncology: overview and principles. Radiology. 2011; 259: 39-56.
68. Madsen SJ, Hirschberg H. Site-specific opening of the blood-brain barrier. Journal of Biophotonics. 2010; 3: 356-367.
69. McDannold N, Arvanitis CD, Vykhodtseva N, Livingstone MS. Temporary disruption of the blood-brain barrier by use of ultrasound and microbubbles: safety and efficacy evaluation in rhesus macaques. Cancer Res. 2012; 72: 3652-3663.
70. Hynynen K, McDannold N, Vykhodtseva N, Jolesz FA. Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology. 2001; 220: 640-646.
71. Treat LH, McDannold N, Vykhodtseva N, Zhang Y, Tam K, Hynynen K. Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI-guided focused ultrasound. Int J Cancer. 2007; 121: 901-907.
72. Kinoshita M, McDannold N, Jolesz FA, Hynynen K. Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. Proc Natl Acad Sci USA. 2006; 103: 11719-11723.
73. Ting CY, Fan CH, Liu HL, et al. Concurrent blood-brain barrier opening and local drug delivery using drug-carrying microbubbles and focused ultrasound for brain glioma treatment. Biomaterials. 2012; 33: 704-712.
74. Demeule M, Regina A, Jodoin J, et al. Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vascular Pharmacology. 2002; 38: 339-348.
75. Ito K, Suzuki H, Horie T, Sugiyama Y. Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm Res. 2005; 22: 1559-1577.
76. Schaich M, Kestel L, Pfirrmann M, et al. A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO. 2009; 20: 175-181.
77. Kruh GD, Belinsky MG. The MRP family of drug efflux pumps. Oncogene. 2003; 22: 7537-7552.
78. Demeule M, Shedid D, Beaulieu E, et al. Expression of multidrug-resistance P-glycoprotein (MDR1) in human brain tumors. Int J Cancer. 2001; 93: 62-66.
79. Sawada T, Kato Y, Sakayori N, Takekawa Y, Kobayashi M. Expression of the multidrug-resistance P-glycoprotein (Pgp, MDR-1) by endothelial cells of the neovasculature in central nervous system tumors. Brain Tumor Pathology. 1999; 16: 23-27.
80. Loscher W, Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx: The Journal of the American Society for Experimental NeuroTherapeutics. 2005; 2: 86-98.
81. Agarwal S, Mittapalli RK, Zellmer DM, et al. Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents. Molecular Cancer Therapeutics. 2012; 11: 2183-2192.
82. Agarwal S, Sane R, Oberoi R, Ohlfest JR, Elmquist WF. Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Reviews in Molecular Medicine. 2011; 13: e17.
83. Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemotherapy and Pharmacology. 1997; 40(Suppl): S13-19.
84. Kemper EM, Boogerd W, Thuis I, Beijnen JH, van Tellingen O. Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours?. Cancer Treatment Reviews. 2004; 30: 415-423.
85. Agarwal S, Hartz AM, Elmquist WF, Bauer B. Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up. Current Pharmaceutical Design. 2011; 17: 2793-2802.
86. Sarin H, Kanevsky AS, Wu H, et al. Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells. Journal of Translational Medicine. 2008; 6: 80.
87. Invernici G, Cristini S, Alessandri G, et al. Nanotechnology advances in brain tumors: the state of the art. Recent Patents on Anti-Cancer Drug Discovery. 2011; 6: 58-69.
88. Rajadhyaksha M, Boyden T, Liras J, El-Kattan A, Brodfuehrer J. Current advances in delivery of biotherapeutics across the blood-brain barrier. Current Drug Discovery Technologies. 2011; 8: 87-101.
89. Wong HL, Wu XY, Bendayan R. Nanotechnological advances for the delivery of CNS therapeutics. Advanced Drug Delivery Reviews. 2012; 64: 686-700.
90. Sarin H, Kanevsky AS, Wu H, et al. Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumors. Journal of Translational Medicine. 2009; 7: 51.
91. Jain A, Jain SK. PEGylation: an approach for drug delivery. A review. Crit Rev Ther Drug Carrier Syst. 2008; 25: 403-447.
92. Huwyler J, Wu D, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA. 1996; 93: 14164-14169.
93. Pang Z, Lu W, Gao H, et al. Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26. Journal of Controlled Release: Official Journal of the Controlled Release Society. 2008; 128: 120-127.
94. Zhang Y, Jeong Lee H, Boado RJ, Pardridge WM. Receptor-mediated delivery of an antisense gene to human brain cancer cells. The Journal of Gene Medicine. 2002; 4: 183-194.
95. Wu D, Yang J, Pardridge WM. Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor. The Journal of Clinical Investigation. 1997; 100: 1804-1812.
96. Mamot C, Drummond DC, Noble CO, et al. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res. 2005; 65: 11631-11638.
97. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science. 1999; 285: 1569-1572.
98. Liu L, Guo K, Lu J, et al. Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood-brain barrier. Biomaterials. 2008; 29: 1509-1517.
99. Goppert TM, Muller RH. Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns. Journal of Drug Targeting. 2005; 13: 179-187.
100. Kreuter J, Ramge P, Petrov V, et al. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm Res. 2003; 20: 409-416.
101. Michaelis K, Hoffmann MM, Dreis S, et al. Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain. The Journal of Pharmacology and Experimental Therapeutics. 2006; 317: 1246-1253.
102. Chao X, Zhang Z, Guo L, et al. A novel magnetic nanoparticle drug carrier for enhanced cancer chemotherapy. PloS one. 2012; 7: e40388.
103. Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H. Nanoparticles as drug delivery systems. Pharmacological Reports: PR. 2012; 64: 1020-1037.
104. Sanson C, Diou O, Thevenot J, et al. Doxorubicin loaded magnetic polymersomes: theranostic nanocarriers for MR imaging and magneto-chemotherapy. ACS nano. 2011; 5: 1122-1140.
105. Wang J, Huang Y, David AE, et al. Magnetic Nanoparticles for MRI of Brain Tumors. Current Pharmaceutical Biotechnology. 2012; 13: 2403-2416.
106. Lakhal S, Wood MJ. Exosome nanotechnology: an emerging paradigm shift in drug delivery: exploitation of exosome nanovesicles for systemic in vivo delivery of RNAi heralds new horizons for drug delivery across biological barriers. BioEssays: News and Reviews in Molecular, Cellular and Developmental Biology. 2011; 33: 737-741.
107. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nature Cell Biology. 2007; 9: 654-659.
108. van Dommelen SM, Vader P, Lakhal S, et al. Microvesicles and exosomes: Opportunities for cell-derived membrane vesicles in drug delivery. Journal of Controlled Release: Official Journal of the Controlled Release Society. 2012; 161: 635-644.
109. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nature Biotechnology. 2011; 29: 341-345.
110. Aasen T, Izpisua Belmonte JC. Isolation and cultivation of human keratinocytes from skin or plucked hair for the generation of induced pluripotent stem cells. Nature Protocols. 2010; 5: 371-382.
111. Buonerba C, Di Lorenzo G, Marinelli A, et al. A comprehensive outlook on intracerebral therapy of malignant gliomas. Critical Reviews in Oncology/Hematology. 2011; 80: 54-68.
112. Westphal M, Ram Z, Riddle V, Hilt D, Bortey E, Executive Committee of the Gliadel Study G. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochirurgica. 2006; 148: 269-275. discussion 275.
113. Brem H, Mahaley MS, Jr., Vick NA, et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg. 1991; 74: 441-446.
114. Zalutsky MR, Reardon DA, Akabani G, et al. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine. 2008; 49: 30-38.
115. Boiardi A, Bartolomei M, Silvani A, et al. Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma. J Neurooncol. 2005; 72: 125-131.
116. Lidar Z, Mardor Y, Jonas T, et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg. 2004; 100: 472-479.
117. Kunwar S, Prados MD, Chang SM, et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol. 2007; 25: 837-844.
118. Sampson JH, Akabani G, Archer GE, et al. Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol. 2008; 10: 320-329.
119. Vogelbaum MA, Iannotti CA. Convection-enhanced delivery of therapeutic agents into the brain. Vinken, PJ, Bruyn, GW ed. Handbook of Clinical Neurology. 2012; 104: 355-362.
120. Fung LK, Shin M, Tyler B, Brem H, Saltzman WM. Chemotherapeutic drugs released from polymers: distribution of 1,3-bis(2-chloroethyl)- 1-nitrosourea in the rat brain. Pharm Res. 1996; 13: 671-682.
121. Krewson CE, Klarman ML, Saltzman WM. Distribution of nerve growth factor following direct delivery to brain interstitium. Brain Research. 1995; 680: 196-206.
122. Engelhard HH. The role of interstitial BCNU chemotherapy in the treatment of malignant glioma. Surgical Neurology. 2000; 53: 458-464.
123. Raghavan R, Brady ML, Rodriguez-Ponce MI, Hartlep A, Pedain C, Sampson JH. Convection-enhanced delivery of therapeutics for brain disease, and its optimization. Neurosurgical Focus. 2006; 20: E12.
124. Allard E, Passirani C, Benoit JP. Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. Biomaterials. 2009; 30: 2302-2318.
125. Tanner PG, Holtmannspotter M, Tonn JC, Goldbrunner R. Effects of drug efflux on convection-enhanced paclitaxel delivery to malignant gliomas: technical note. Neurosurgery. 2007; 61: E880-882. discussion E882.
126. Weber F, Asher A, Bucholz R, et al. Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol. 2003; 64: 125-137.
127. Weaver M, Laske DW. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol. 2003; 65: 3-13.
128. Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nature Medicine. 1997; 3: 1362-1368.
129. Chen MY, Lonser RR, Morrison PF, Governale LS, Oldfield EH. Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. J Neurosurg. 1999; 90: 315-320.
130. Stukel JM, Caplan MR. Targeted drug delivery for treatment and imaging of glioblastoma multiforme. Expert Opin Drug Deliv. 2009; 6: 705-718.
131. Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol. 2010; 12: 871-881.
132. Sampson JH, Archer G, Pedain C, et al. Poor drug distribution as a possible explanation for the results of the PRECISE trial. J Neurosurg. 2010; 113: 301-309.
133. Bogdahn U, Hau P, Stockhammer G, et al. Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol. 2011; 13: 132-142.
134. Shahar T, Ram Z, Kanner AA. Convection-enhanced delivery catheter placements for high-grade gliomas: complications and pitfalls. J Neurooncol. 2012; 107: 373-378.
135. Huo T, Barth RF, Yang W, et al. Preparation, biodistribution and neurotoxicity of liposomal cisplatin following convection enhanced delivery in normal and F98 glioma bearing rats. PloS one. 2012; 7: e48752.
136. Ding D, Kanaly CW, Bigner DD, et al. Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1. J Neurooncol. 2010; 98: 1-7.
137. Sugiyama S, Saito R, Nakamura T, et al. Safety and feasibility of convection-enhanced delivery of nimustine hydrochloride co-infused with free gadolinium for real-time monitoring in the primate brain. Neurological Research. 2012; 34: 581-587.
138. Yin D, Richardson RM, Fiandaca MS, et al. Cannula placement for effective convection-enhanced delivery in the nonhuman primate thalamus and brainstem: implications for clinical delivery of therapeutics. J Neurosurg. 2010; 113: 240-248.
139. Richardson RM, Kells AP, Martin AJ, et al. Novel platform for MRI-guided convection-enhanced delivery of therapeutics: preclinical validation in nonhuman primate brain. Stereotactic and Functional Neurosurgery. 2011; 89: 141-151.
140. Mehta AI, Choi BD, Raghavan R, et al. Imaging of convection enhanced delivery of toxins in humans. Toxins. 2011; 3: 201-206.
141. Lewis GK, Jr., Schulz ZR, Pannullo SC, Southard TL, Olbricht WL. Ultrasound-assisted convection-enhanced delivery to the brain in vivo with a novel transducer cannula assembly. J Neurosurg. 2012; 117: 1128-1140.
142. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335-2342.
143. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355: 2542-2550.
144. Thompson EM, Frenkel EP, Neuwelt EA. The paradoxical effect of bevacizumab in the therapy of malignant gliomas. Neurology. 2011; 76: 87-93.
145. Ma J, Chen CS, Blute T,Waxman DJ. Antiangiogenesis enhances intratumoral drug retention. Cancer Res. 2011; 71: 2675-2685.
146. Wurdinger T, Tannous BA. Glioma angiogenesis: Towards novel RNA therapeutics. Cell Adhesion and Migration. 2009; 3: 230-235.
147. Ma J,Waxman DJ. Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib. Molecular Cancer Therapeutics. 2008; 7: 79-89.
148. Ferrara N. VEGF as a therapeutic target in cancer. Oncology. 2005; 69 (Suppl 3): 11-16.
149. Nghiemphu PL, Liu W, Lee Y, et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology. 2009; 72: 1217-1222.
150. Narayana A, Kunnakkat SD, Medabalmi P, et al. Change in pattern of relapse after anti-angiogenic therapy in high-grade glioma. International Journal of Radiation Oncology, Biology, Physics. 2012; 82: 77-82.
151. de Groot JF, Fuller G, Kumar AJ, et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol. 2010; 12: 233-242.